Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URT010
MIFTS: 45

Ureteral Obstruction

Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ureteral Obstruction

About this section

MalaCards integrated aliases for Ureteral Obstruction:

Name: Ureteral Obstruction 12 54 15

External Ids:

Disease Ontology 12 DOID:5199
ICD9CM 34 593.4
UMLS 71 C0029866
Sources

Summaries for Ureteral Obstruction

About this section
MalaCards based summary : Ureteral Obstruction is related to hydronephrosis and renal fibrosis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are TGF-Beta Pathway and PAK Pathway. The drugs Silodosin and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Ureteral Obstruction

About this section

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 343)
# Related Disease Score Top Affiliating Genes
1 hydronephrosis 32.1 TGFB1 SLC12A1 AQP2 AGTR2
2 renal fibrosis 31.8 TGFB1 NFE2L2 ENG CTNNB1 BMP7 AGTR1
3 urinary tract obstruction 31.7 TGFB1 PTGS2 BMP7 AQP2 AGTR1
4 obstructive nephropathy 31.7 TGFB1 AGTR2 ADAMTS1
5 pyelonephritis 31.5 TGFB1 IL10 AQP2
6 chronic kidney disease 31.2 TGFB1 IL10 EPO BMP7 AQP2 AGTR1
7 vesicoureteral reflux 1 31.2 TGFB1 AGTR2 AGTR1
8 kidney disease 31.1 TGFB1 SLC12A1 EPO BMP7 AQP2 AGTR2
9 posterior urethral valves 30.8 TGFB1 AGTR2 AGTR1
10 nephrosclerosis 30.4 TGFB1 BMP7 AGTR1
11 adenocarcinoma 30.4 VEGFC TP53 TGFB1 PTGS2 CTNNB1
12 ureteral disease 30.4 TGFB1 BMP7 AQP2 AGTR1
13 glandular cystitis 30.4 TP53 CTNNB1
14 adenomyosis 30.3 TP53 PTGS2 CTNNB1
15 cervical cancer 30.3 VEGFC TP53 TGFB1 PTGS2 NFE2L2 IL10
16 prostatitis 30.2 TP53 TGFB1 PTGS2 IL10
17 polycystic kidney disease 30.2 EPO CTNNB1 AQP2 AGTR1
18 lymphangioma 30.1 VEGFC TP53 PTGS2 CTNNB1
19 cholangiocarcinoma 30.1 VEGFC TP53 PTGS2 CTNNB1
20 myelofibrosis 29.9 TP53 TGFB1 EPO ENG
21 bladder urothelial carcinoma 29.9 VEGFC TP53 NFE2L2 CTNNB1
22 squamous cell carcinoma 29.9 VEGFC TP53 PTGS2 NFE2L2 CTNNB1
23 gallbladder cancer 29.8 VEGFC TP53 PTGS2 CTNNB1
24 diabetes mellitus 29.5 TP53 TGFB1 PTGS2 NFE2L2 IL10 EPO
25 vascular disease 29.5 TP53 TGFB1 PTGS2 PDGFA NOX4 NFE2L2
26 hypertension, essential 28.5 VEGFC TP53 TGFB1 SLC9A3 SLC12A1 PTGS2
27 fibrosis of extraocular muscles, congenital, 1 10.8
28 endometriosis 10.7
29 acute kidney failure 10.7
30 retroperitoneal fibrosis 10.7
31 juvenile myasthenia gravis 10.6 TGFB1 IL10
32 aneurysm 10.6
33 anuria 10.6
34 leukoregulin 10.6 TGFB1 PTGS2
35 vulvar intraepithelial neoplasia 10.5 TP53 CTNNB1
36 familial vesicoureteral reflux 10.5 TGFB1 AGTR2
37 cataract 30 10.5 TGFB1 CTNNB1 AGTR1
38 aortic aneurysm 10.5
39 acute cystitis 10.5
40 end stage renal disease 10.5
41 bone squamous cell carcinoma 10.5 TP53 ENG CTNNB1
42 twin-to-twin transfusion syndrome 10.5 VEGFC ENG AGTR1
43 adult teratoma 10.5 TP53 ENG
44 van buchem disease 10.4 TGFB1 SFRP4 CTNNB1
45 dent disease 1 10.4 SLC9A3 SLC12A1 LRP2
46 sclerosteosis 10.4 TGFB1 SFRP4 CTNNB1
47 aortic aneurysm, familial abdominal, 1 10.4
48 esophagus adenocarcinoma 10.4 TP53 PTGS2 CTNNB1
49 colonic benign neoplasm 10.4 TP53 PTGS2 CTNNB1
50 osteonecrosis 10.4 IL10 ENG BMP7

Graphical network of the top 20 diseases related to Ureteral Obstruction:



Diseases related to Ureteral Obstruction
Sources

Symptoms & Phenotypes for Ureteral Obstruction

About this section

MGI Mouse Phenotypes related to Ureteral Obstruction:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.54 AGTR1 AGTR2 BMP7 CTNNB1 ENG EPO
2 homeostasis/metabolism MP:0005376 10.49 ADAMTS1 AGTR1 AGTR2 AQP2 CTNNB1 ENG
3 growth/size/body region MP:0005378 10.47 ADAMTS1 AGTR1 AGTR2 AQP2 BMP7 CTNNB1
4 mortality/aging MP:0010768 10.41 ADAMTS1 AGTR1 AGTR2 AQP2 BMP7 CTNNB1
5 behavior/neurological MP:0005386 10.4 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
6 hematopoietic system MP:0005397 10.4 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 ENG
7 digestive/alimentary MP:0005381 10.38 AGTR2 BMP7 CTNNB1 ENG IL10 LRP2
8 immune system MP:0005387 10.34 AGTR1 AGTR2 BMP7 CTNNB1 EPO IL10
9 embryo MP:0005380 10.3 BMP7 CTNNB1 ENG EPO IL10 LRP2
10 integument MP:0010771 10.29 AGTR2 AQP2 BMP7 CTNNB1 ENG EPO
11 endocrine/exocrine gland MP:0005379 10.25 ADAMTS1 AGTR2 BMP7 CTNNB1 IL10 LRP2
12 craniofacial MP:0005382 10.23 BMP7 CTNNB1 ENG IL10 LRP2 NFE2L2
13 adipose tissue MP:0005375 10.2 ADAMTS1 AGTR1 AGTR2 NFE2L2 PTGS2 SLC9A3
14 renal/urinary system MP:0005367 10.16 ADAMTS1 AGTR1 AGTR2 AQP2 BMP7 CTNNB1
15 nervous system MP:0003631 10.13 AGTR1 AGTR2 BMP7 CTNNB1 ENG IL10
16 muscle MP:0005369 10.1 AGTR2 CTNNB1 ENG EPO IL10 NOX4
17 limbs/digits/tail MP:0005371 10 BMP7 CTNNB1 EPO IL10 LRP2 SFRP4
18 reproductive system MP:0005389 9.97 ADAMTS1 AQP2 BMP7 CTNNB1 IL10 LRP2
19 neoplasm MP:0002006 9.91 AGTR2 CTNNB1 IL10 NFE2L2 PTGS2 TGFB1
20 respiratory system MP:0005388 9.77 BMP7 CTNNB1 ENG EPO IL10 LRP2
21 skeleton MP:0005390 9.44 AGTR2 BMP7 CTNNB1 EPO IL10 LRP2
Sources

Drugs & Therapeutics for Ureteral Obstruction

About this section

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Silodosin Approved Phase 4 160970-54-7
2
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
3
Opium Approved, Illicit Phase 4 8008-60-4
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
6
Belladonna Approved, Experimental Phase 4
7
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
8
BCG vaccine Investigational Phase 4
9 Tolterodine tartrate Phase 4 124937-52-6
10 Analgesics Phase 4
11 Narcotics Phase 4
12 Opium Poppy Phase 4
13 Butylscopolammonium Bromide Phase 4
14 Adrenergic alpha-Antagonists Phase 4
15 Adrenergic Agents Phase 4
16 Adrenergic Antagonists Phase 4
17 Adrenergic alpha-1 Receptor Antagonists Phase 4
18 Neurotransmitter Agents Phase 4
19 Immunologic Factors Phase 4
20 Adjuvants, Immunologic Phase 4
21 Alkylating Agents Phase 4
22 Anti-Bacterial Agents Phase 4
23 Vaccines Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Mitomycins Phase 4
26 Hemostatics Phase 3
27 Fibrin Tissue Adhesive Phase 3
28 Coagulants Phase 3
29
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
30
Tamoxifen Approved Phase 2 10540-29-1 2733526
31
Iodine Approved, Investigational Phase 2 7553-56-2 807
32
Triclosan Approved, Investigational Phase 2 3380-34-5 5564
33
Mirabegron Approved Phase 2 223673-61-8 9865528
34
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
35
Gemcitabine Approved Phase 2 95058-81-4 60750
36 Anti-Inflammatory Agents Phase 2
37 Hormones Phase 2
38 Hormone Antagonists Phase 2
39 Antineoplastic Agents, Hormonal Phase 2
40 Estrogen Receptor Modulators Phase 2
41 glucocorticoids Phase 2
42 Estrogens Phase 2
43 Estrogen Antagonists Phase 2
44 Estrogen Receptor Antagonists Phase 2
45 Adrenergic beta-Agonists Phase 2
46 Adrenergic Agonists Phase 2
47 Adrenergic beta-3 Receptor Agonists Phase 2
48 Anti-Infective Agents Phase 2
49 Antiviral Agents Phase 2
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTAâ„¢) in Ureteral Obstruction: Prospective, Multi-center, Open Label Study Unknown status NCT01788865 Phase 4
2 Effect of a Silicone Hydrocoated Double Loop Ureteral Stent on Symptoms and Quality of Life in Patients Undergoing F-URS for Kidney Stone; a Comparative Randomized Multicenter Clinical Study. Unknown status NCT02489656 Phase 4
3 Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
4 A 4-week, Double-blind, Randomized, Comparative and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones. Completed NCT01533389 Phase 4 Silodosin;Placebo
5 Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults Completed NCT00301470 Phase 4
6 The Use of Belladonna and Opium (B&O) Suppository in the Treatment of Postoperative Stent Pain: A Randomized, Double-Blinded Control Study Completed NCT03332056 Phase 4 Belladonna and Opium
7 The Effect of Daily Versus Twice Per Day Tamsulosin on Ureteral Stent Symptoms Following Ureteroscopy for Nephrolithiasis Enrolling by invitation NCT03799120 Phase 4 Tamsulosin BID
8 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
9 Application of the Biological Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplant Completed NCT01631448 Phase 3
10 Comparison of the Efficacy of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction: A Prospective Randomized Controlled Trial Based on Exploratory Research Unknown status NCT01823575 Phase 2
11 A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
12 Study of Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in the Treatment of Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
13 Assessment of Bacterial Adherence and Biofilm Formation on a Triclosan Loaded Ureteral Stent: A Phase II Study Completed NCT00250406 Phase 2
14 A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02) Completed NCT02744430 Phase 2 Mirabegron
15 A Randomized Control Trial Comparing Single to Multiple Application Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
16 A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
17 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Unknown status NCT02160652
18 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance in Children With Scintigraphically Prooved Obstruction. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431
19 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
20 Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome Unknown status NCT02812212
21 Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study Unknown status NCT01564303 Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
22 Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes Unknown status NCT02123082
23 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
24 Laparoscopic Pyeloplasty: A Registry and Database Completed NCT00169650
25 Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent Completed NCT00166361
26 Evaluation of Ureteral Length Measurement by Computed Tomography (CT) to Actual Ureteral Length Measured by Ureteral Catheterization Completed NCT01542593
27 Lower UTI Evaluation in Women With Uterine Leiomyomata Completed NCT01123603
28 Retrospective Study of Patients Undergoing Percutaneous Intervention of the Transplant Renal Artery Stenosis (TRAS Study) Completed NCT04225338
29 Boston Scientific Double-J Ureteral Stent Postmarket Patient Registry Recruiting NCT04197583
30 Post-Marketing Follow-Up of Long-term Type Ureteral Stent Set Recruiting NCT04250090
31 Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population Recruiting NCT02140970 Ibuprofen;Placebo
32 Prospective Multicenter Observational Study of Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Recruiting NCT02419339
33 Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial Recruiting NCT03482089
34 A Prospective Cohort Study of Idiopathic Retroperitoneal Fibrosis in China Recruiting NCT04312854
35 Is Routine Urinary Bladder Catheterization Necessary After Ureteroscopy and Double J Stent Placement? Recruiting NCT03713411
36 Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA) Recruiting NCT03100409
37 Phase-I Feasibility Trial To Study The Safety Of Laser Tissue Welding For Sealing Resected Kidney Surfaces After Laparoscopic Partial Nephrectomy Active, not recruiting NCT02061605
38 Renal Manifestations of IBD Not yet recruiting NCT04301297
39 The RELIEFâ„¢ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position Not yet recruiting NCT03266770
40 Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial Suspended NCT03709992 Trospium Chloride;Tamsulosin
41 Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Terminated NCT02713633
42 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine for the Management of Pain After Surgical Correction of Ureteropelvic Junction Stenosis Terminated NCT00930046
43 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of Ureteropelvic Junction Obstruction Withdrawn NCT00199472

Search NIH Clinical Center for Ureteral Obstruction

Sources

Genetic Tests for Ureteral Obstruction

About this section
Sources

Anatomical Context for Ureteral Obstruction

About this section

MalaCards organs/tissues related to Ureteral Obstruction:

40
Kidney, Prostate, Bone, Endothelial, Colon, Cervix, Monocytes
Sources

Publications for Ureteral Obstruction

About this section

Articles related to Ureteral Obstruction:

(show top 50) (show all 4915)
# Title Authors PMID Year
1
IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. 61 54
19536084 2009
2
Angiotensin II type 1 receptor blockade prevents decrease in adult stem-like cells in kidney after ureteral obstruction. 54 61
17692840 2007
3
Snail1 is involved in the renal epithelial-mesenchymal transition. 54 61
17692821 2007
4
Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. 54 61
16820795 2006
5
Elevated plasma concentrations of transforming growth factor-beta 1 in patients with unilateral ureteral obstruction. 54 61
16315065 2005
6
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. 61 54
15153562 2004
7
Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. 61 54
10894795 2000
8
A review on urinary proteins in outflow disease of the upper urinary tract. 61 54
10841920 2000
9
Increased expression of TGF-beta1 but not of its receptors contributes to human obstructive nephropathy. 54 61
10594789 1999
10
Effects of experimental ureteral obstruction on platelet-derived growth factor-A and type I procollagen expression in fetal metanephric kidneys. 61 54
7819000 1994
11
SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. 61 54
1895664 1991
12
MiR-542-3p drives renal fibrosis by targeting AGO1 in vivo and in vitro. 61
32470449 2020
13
FoxM1 inhibition ameliorates renal interstitial fibrosis by decreasing extracellular matrix and epithelial-mesenchymal transition. 61
32513569 2020
14
iTRAQ-based proteomics and in vitro experiments reveals essential roles of ACE and AP-N in the renin-angiotensin system-mediated congenital ureteropelvic junction obstruction. 61
32416091 2020
15
Poricoic acid A activates AMPK to attenuate fibroblast activation and abnormal extracellular matrix remodelling in renal fibrosis. 61
32460034 2020
16
MiR-200b/c family inhibits renal fibrosis through modulating epithelial-to-mesenchymal transition via targeting fascin-1/CD44 axis. 61
32220622 2020
17
Protective effects of Amygdalus mongolica on rats with renal fibrosis based on serum metabolomics. 61
32278030 2020
18
Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway. 61
32348836 2020
19
Long non-coding RNA NEAT1 sponges miR-129 to modulate renal fibrosis by regulation of collagen I. 61
32475133 2020
20
High-molecular weight hyaluronan attenuates tubulointerstitial scarring in kidney injury. 61
32396531 2020
21
Utility of urinary organic anion transporter 5 as an early biomarker of obstructive nephropathy. 61
32497308 2020
22
Alteration of N6-methyladenosine epitranscriptome profile in unilateral ureteral obstructive nephropathy. 61
32543222 2020
23
Urinary kidney injury molecule-1: a novel biomarker to monitor renal function in patients with unilateral ureteral obstruction. 61
32507943 2020
24
Temporal Trends and Practice Patterns for Inpatient Management of Malignant Extrinsic Ureteral Obstruction in the United States. 61
32340482 2020
25
Amoxicillin-Induced Crystalline Nephropathy Presenting as Ureteral Obstruction. 61
32233648 2020
26
Use of a shaving technique for surgical management of partial ureteral obstruction due to endometriosis. 61
32387271 2020
27
Dual Soluble Epoxide Hydrolase Inhibitor/PPAR-γ Agonist Attenuates Renal Fibrosis. 61
32569747 2020
28
Ablation of Gadd45β ameliorates the inflammation and renal fibrosis caused by unilateral ureteral obstruction. 61
32570293 2020
29
Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis. 61
32281211 2020
30
A negative feedback loop between JNK-associated leucine zipper protein and TGF-β1 regulates kidney fibrosis. 61
32504044 2020
31
Inhibition of ROCK2 alleviates renal fibrosis and the metabolic disorders in the proximal tubular epithelial cells. 61
32490513 2020
32
Chrysophanol ameliorates renal interstitial fibrosis by inhibiting the TGF-β/Smad signaling pathway. 61
32511988 2020
33
Tubule-derived exosomes play a central role in fibroblast activation and kidney fibrosis. 61
32139089 2020
34
Loss of IL-27Rα Results in Enhanced Tubulointerstitial Fibrosis Associated with Elevated Th17 Responses. 61
32522836 2020
35
Xanthogranulomatous Ureteritis Mimicking Ureteral Involvement by Cancer in a Radical Cystectomy Specimen. 61
32493143 2020
36
Impact of Colloidal Fluid on Stent Failure Under Extrinsic Ureteral Obstruction: An <i>In Vitro</i> Experimental Study. 61
32539472 2020
37
Inguinal herniorrhaphy related ureteral obstruction in kidney transplant recipient: A rare but crucial complication. 61
32122757 2020
38
IgG4-related aortitis/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease. 61
32366271 2020
39
Maternal endotoxemia induces renal collagen deposition in adult offspring: Role of NADPH oxidase/TGF-β1/MMP-2 signaling pathway. 61
32081684 2020
40
Role of Chemical Exchange Saturation Transfer and Magnetization Transfer MRI in Detecting Metabolic and Structural Changes of Renal Fibrosis in an Animal Model at 3T. 61
32323504 2020
41
Inguinal Herniation After Living Donor Kidney Transplantation: A Case Report. 61
32448665 2020
42
Interventions and experience after complicated total cystectomy in a dog with transitional cell carcinoma. 61
31602683 2020
43
Acute Ureteral Obstruction by Deeply Inserted Menstrual Cup. 61
32087214 2020
44
Acute on chronic kidney disease in cats: Etiology, clinical and clinicopathologic findings, prognostic markers, and outcome. 61
32445217 2020
45
Retrospective Analysis of the Role of Antibiotic Prophylaxis in the Placement and Replacement of Percutaneous Nephrostomy Catheters in Patients with Malignant Ureteral Obstruction. 61
31800348 2020
46
An unusual complication of urinary stone disease: Spontaneous ureteral rupture. 61
31924441 2020
47
Robotic Versus Open Ureteroneocystostomy: Is There a Robotic Benefit? 61
32423300 2020
48
Evaluation of dynamic thiol-disulphide homeostasis in obstructive uropathy. 61
31955364 2020
49
Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo. 61
32454122 2020
50
Ureteroenteric anastomosis in orthotopic neobladder creation: do urinary tract infections impact stricture rate? 61
32468109 2020
Sources

Variations for Ureteral Obstruction

About this section
Sources

Expression for Ureteral Obstruction

About this section
Search GEO for disease gene expression data for Ureteral Obstruction.
Sources

Pathways for Ureteral Obstruction

About this section

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
TGF-Beta Pathway 63
Show member pathways
 13.39 VEGFC TP53 TGFB1 PDGFA IL10 EPO
2
PAK Pathway 63
Show member pathways
 13.22 VEGFC TGFB1 PDGFA NOX4 IL10 CTNNB1
3
PI3K-Akt signaling pathway 36
Show member pathways
 12.89 VEGFC TP53 PTGS2 PDGFA EPO CTNNB1
4
p70S6K Signaling 63
Show member pathways
 12.75 VEGFC TGFB1 PTGS2 PDGFA BMP7 AGTR2
5
Immune response IL-23 signaling pathway 22
Show member pathways
 12.47 TP53 PDGFA IL10 CTNNB1 AGTR1
6
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.32 VEGFC TGFB1 PDGFA CTNNB1 BMP7
7
Human Embryonic Stem Cell Pluripotency 63
Show member pathways
 12.3 TGFB1 PDGFA NOX4 CTNNB1 BMP7
8
Wnt / Hedgehog / Notch 4
12.16 TGFB1 ENG CTNNB1 BMP7
9
Colorectal Cancer Metastasis 63
12.08 TP53 TGFB1 PTGS2 CTNNB1
10
Pathways in cancer 36
12 VEGFC TP53 TGFB1 PTGS2 PDGFA NFE2L2
11
Fluid shear stress and atherosclerosis 36
11.97 TP53 PDGFA NFE2L2 CTNNB1
12
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 11.94 VEGFC TP53 TGFB1 PDGFA IL10 BMP7
13
Spinal Cord Injury 1
11.86 TP53 TGFB1 PTGS2 NOX4
14
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.79 TGFB1 ENG BMP7
15
Interleukin-4 and 13 signaling 65
11.79 TP53 TGFB1 PTGS2 IL10
16
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 60
Show member pathways
 11.71 TGFB1 AGTR2 AGTR1
17
AGE-RAGE signaling pathway in diabetic complications 36
11.67 VEGFC TGFB1 NOX4 AGTR1
18
Transcription_P53 signaling pathway 22
11.62 TP53 TGFB1 CTNNB1 BMP7
19
Endochondral Ossification 1
11.61 TGFB1 BMP7 ADAMTS1
20
TGF-beta Receptor Signaling (WikiPathways) 1
11.54 TGFB1 ENG CTNNB1
21
HIF1Alpha Pathway 63
11.5 VEGFC TP53 EPO
22
Hepatitis C and Hepatocellular Carcinoma 1
11.45 TP53 TGFB1 PTGS2
23
Differentiation Pathway 1
11.4 TGFB1 PDGFA EPO
24
Angiogenesis (CST) 4
11.3 VEGFC TGFB1 PTGS2 ENG ADAMTS1
25
Lung fibrosis 1
11.26 TGFB1 PDGFA NFE2L2 BMP7
26
Photodynamic therapy-induced HIF-1 survival signaling 1
11.25 TP53 PTGS2 EPO
27
Cytokines and Inflammatory Response 1
11.04 TGFB1 PDGFA IL10
28
G-protein signaling_Rap2B regulation pathway 22
10.93 VEGFC TGFB1 PDGFA IL10 BMP7
Sources

GO Terms for Ureteral Obstruction

About this section

Cellular components related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 VEGFC TGFB1 SFRP4 PDGFA IL10 EPO
2 cell surface GO:0009986 9.63 TGFB1 SLC9A3 SFRP4 PDGFA EPO ENG
3 platelet alpha granule lumen GO:0031093 9.43 VEGFC TGFB1 PDGFA
4 apical plasma membrane GO:0016324 9.35 SLC9A3 SLC12A1 NOX4 LRP2 AQP2
5 cell GO:0005623 9.23 TGFB1 SLC9A3 SLC12A1 NOX4 NFE2L2 CTNNB1

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 TP53 TGFB1 NFE2L2 IL10 ENG CTNNB1
2 negative regulation of apoptotic process GO:0043066 10.04 TP53 PTGS2 LRP2 IL10 EPO CTNNB1
3 positive regulation of cell proliferation GO:0008284 10.02 VEGFC TGFB1 PTGS2 PDGFA EPO CTNNB1
4 angiogenesis GO:0001525 10.01 VEGFC PTGS2 PDGFA ENG
5 inflammatory response GO:0006954 10 TGFB1 PTGS2 NOX4 NFE2L2 AGTR2 AGTR1
6 positive regulation of gene expression GO:0010628 10 TP53 TGFB1 SFRP4 NFE2L2 ENG CTNNB1
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 TGFB1 PDGFA NOX4 EPO
8 positive regulation of transcription, DNA-templated GO:0045893 9.97 TP53 TGFB1 NFE2L2 IL10 EPO CTNNB1
9 heart development GO:0007507 9.95 TP53 TGFB1 LRP2 ENG CTNNB1
10 response to hypoxia GO:0001666 9.94 VEGFC TGFB1 NOX4 EPO
11 regulation of cell proliferation GO:0042127 9.93 TP53 TGFB1 PTGS2 CTNNB1 AGTR1
12 response to organic substance GO:0010033 9.89 TGFB1 PTGS2 IL10
13 positive regulation of protein kinase B signaling GO:0051897 9.89 TGFB1 PDGFA NOX4 LRP2 ENG
14 BMP signaling pathway GO:0030509 9.88 TGFB1 ENG BMP7
15 cellular response to hypoxia GO:0071456 9.88 TP53 PTGS2 NFE2L2 BMP7
16 cellular response to mechanical stimulus GO:0071260 9.87 TGFB1 PTGS2 ENG
17 positive regulation of apoptotic process GO:0043065 9.87 TP53 TGFB1 SFRP4 PTGS2 NOX4 CTNNB1
18 cellular response to growth factor stimulus GO:0071363 9.86 TGFB1 LRP2 CTNNB1
19 response to estradiol GO:0032355 9.86 TGFB1 PTGS2 CTNNB1 BMP7
20 vasculogenesis GO:0001570 9.84 TGFB1 ENG CTNNB1
21 positive regulation of MAP kinase activity GO:0043406 9.83 TGFB1 PDGFA NOX4
22 positive regulation of blood vessel endothelial cell migration GO:0043536 9.81 VEGFC TGFB1 NFE2L2
23 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.8 TGFB1 ENG BMP7
24 positive regulation of cell division GO:0051781 9.8 VEGFC TGFB1 PDGFA
25 kidney development GO:0001822 9.8 CTNNB1 BMP7 AGTR2 AGTR1 ADAMTS1
26 negative regulation of cell cycle GO:0045786 9.79 TGFB1 PTGS2 BMP7
27 positive regulation of epithelial to mesenchymal transition GO:0010718 9.79 TGFB1 CTNNB1 BMP7
28 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.77 TP53 TGFB1 IL10
29 negative regulation of mitotic cell cycle GO:0045930 9.76 TP53 TGFB1 IL10
30 epithelial to mesenchymal transition GO:0001837 9.73 TGFB1 ENG CTNNB1 BMP7
31 cardiac septum morphogenesis GO:0060411 9.71 TP53 BMP7
32 morphogenesis of embryonic epithelium GO:0016331 9.71 VEGFC CTNNB1
33 cell activation GO:0001775 9.71 TGFB1 PDGFA
34 cellular response to fluid shear stress GO:0071498 9.7 PTGS2 NFE2L2
35 positive regulation of histone deacetylation GO:0031065 9.7 TP53 TGFB1
36 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.7 TP53 TGFB1
37 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.69 TP53 TGFB1
38 response to salt stress GO:0009651 9.69 TP53 EPO
39 response to vitamin D GO:0033280 9.69 TGFB1 PTGS2 BMP7
40 salivary gland morphogenesis GO:0007435 9.68 TGFB1 BMP7
41 regulation of protein import into nucleus GO:0042306 9.68 TGFB1 AGTR2
42 angiotensin-activated signaling pathway GO:0038166 9.68 AGTR2 AGTR1
43 negative regulation of neuroblast proliferation GO:0007406 9.67 TP53 TGFB1
44 regulation of removal of superoxide radicals GO:2000121 9.65 NFE2L2 BMP7
45 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.65 TP53 NFE2L2
46 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.65 TP53 NFE2L2
47 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.63 PTGS2 EPO
48 aging GO:0007568 9.63 TGFB1 PTGS2 NOX4 NFE2L2 IL10 EPO
49 central nervous system vasculogenesis GO:0022009 9.61 ENG CTNNB1
50 renin-angiotensin regulation of aldosterone production GO:0002018 9.6 AGTR2 AGTR1

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 VEGFC TP53 TGFB1 SLC9A3 SFRP4 PTGS2
2 cytokine activity GO:0005125 9.67 TGFB1 IL10 EPO BMP7
3 type I transforming growth factor beta receptor binding GO:0034713 9.32 TGFB1 ENG
4 type II transforming growth factor beta receptor binding GO:0005114 9.26 TGFB1 ENG
5 growth factor activity GO:0008083 9.02 VEGFC TGFB1 PDGFA IL10 BMP7
6 angiotensin type II receptor activity GO:0004945 8.96 AGTR2 AGTR1
Sources

Sources for Ureteral Obstruction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....